Study shows promising results for new vaccine focused on colorectal, pancreatic cancer

A new study reveals promising results for a vaccine focused on colorectal and pancreatic cancer. Researchers from the University of California, Los Angeles (UCLA) said that patients developed “strong immune reactions” to the new vaccine and remained disease -free.

The new vaccine, ELI-002 2P, stimulates the immune system to focus on the most common mutations of cancer, as identified by researchers. Researchers say that the vaccine can cause powerful and sustainable immune response that can help prevent or delay the repetition of cancer in high -risk patients. For the context, researchers discovered that the median relapse -free survival was 16.33 months and the median overall survival was 28.94 months, both of which exceed historical standards.

“This is an exciting progress for patients with scratch-driven cancers, in particular pancreatic cancer, where repetition after standard treatment is almost a given and effective therapies limited,” said first author of the study, Dr. ZEV Wainberg, professor in medicine at the David Geffen School of Medicine at UCLA. “We saw that patients who developed strong immune response on the vaccine remained disease -free and survived much longer than expected.”

Important results in vaccine focused on colorectal and pancreatic canches

Doctors followed 25 patients with pancreas ductal adenocarcinoma or colorectal cancer. All patients had previously undergone surgery and showed signs of minimal remaining diseases, or traces of DNA of cancer in the blood that often indicate a relapse.

Each patient received a series of injections with the vaccine. An important finding is that 84% of patients generated scratch-specific T cells that can focus on cancers that are difficult to treat. Another important finding is that in 24% of patients (a total of 6) biomarkers associated with the tumor were completely deleted.

“Targeting of scratch has long been considered one of the difficult challenges in cancer therapy,” Wainberg said in a statement. “This study shows that the ELI-002 2P vaccine can train the immune system safely and effectively to recognize and combat mutations of cancer. It offers a promising approach for generating precise and sustainable immune reactions without the complexity or costs of fully personalized vaccines.”

The vaccine can be a game changer for black people, who are disproportionately hit by both cancers. According to the American Cancer Society, Black men and women have higher incidence rates and a greater chance of death compared to other racial groups. They are about 20% more likely to be diagnosed and about 40% more likely to die from the disease.

With regard to pancreatic cancer, black Americans have the highest incidence rates among all racial and ethnic groups. Studies show that the incidence is 50% to 90% higher with Afro -Mamerikans compared to other groups, according to the National Institutes of Health. Black patients are also diagnosed more often in later stages, which complicate the treatment.

Related content: raise your excellence: the unyielding vision of pastor Jamal Bryant in the struggle for economic and social justice